Literature DB >> 8650849

[Positron emission tomography in diagnosis of renal cell carcinoma].

R Bachor1, J Kotzerke, H W Gottfried, E Brändle, S N Reske, R Hautmann.   

Abstract

PET is a new method for staging malignant tumors; the metabolism is examined and not the morphology. In this study the staging of renal cell carcinoma (RCC) by PET was investigated. In 29 patients PET with fluorodeoxyglucose (FDG) was carried out preoperatively; the PET results were compared to the histology of the OR specimen. In 26 patients a RCC was found histologically, which was diagnosed correctly by PET in 20 patients; in 6 patients a false-negative PET result was obtained. An angiomyolipoma, a pericytoma and a pheochromocytoma showed a false-positive PET result. For lymph-node staging positive nodes were found in 3 patients which was correct; no false-negative result was obtained. In 25 patients the PET result was true-positive; once a false-positive finding occurred. In conclusion, PET offers the advantage that no allergy to FDG is known and a pacemaker or metal implants are not contraindications; in diagnosing RCC, according to our results there is no further advantage of FDG-PET in comparison to standard methods; for lymph-node staging the results are equivalent

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8650849

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  13 in total

1.  Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT.

Authors:  Nicolas Aide; Olivier Cappele; Philippe Bottet; Henri Bensadoun; Armelle Regeasse; François Comoz; Franck Sobrio; Gérard Bouvard; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-04       Impact factor: 9.236

2.  2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses.

Authors:  Rakesh Kumar; Anil Chauhan; Paras Lakhani; Yan Xiu; Hongming Zhuang; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

Review 3.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

Review 4.  Functional imaging of renal cell carcinoma.

Authors:  Nathan Lawrentschuk; Ian D Davis; Damien M Bolton; Andrew M Scott
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

5.  Malignant epithelioid angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography.

Authors:  Eliney Faria; Francesco Turturro; Priya Rao; Surena F Matin
Journal:  Clin Genitourin Cancer       Date:  2013-06-20       Impact factor: 2.872

Review 6.  Imaging for Metastatic Renal Cell Carcinoma.

Authors:  Soumya V L Vig; Elcin Zan; Stella K Kang
Journal:  Urol Clin North Am       Date:  2020-06-11       Impact factor: 2.241

Review 7.  [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].

Authors:  S Machtens; A R Boerner; M Hofmann; W H Knapp; U Jonas
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

8.  [1-(11)C]acetate uptake is not increased in renal cell carcinoma.

Authors:  J Kotzerke; C Linné; M Meinhardt; J Steinbach; M Wirth; G Baretton; N Abolmaali; B Beuthien-Baumann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-30       Impact factor: 9.236

9.  FDG PET or PET/CT in evaluation of renal angiomyolipoma.

Authors:  Chun-Yi Lin; Hui-Yi Chen; Hueisch-Jy Ding; Kuo-Yang Yen; Chia-Hung Kao
Journal:  Korean J Radiol       Date:  2013-02-22       Impact factor: 3.500

Review 10.  Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.

Authors:  Hsin-Yi Wang; Hueisch-Jy Ding; Jin-Hua Chen; Chih-Hao Chao; Yu-Yu Lu; Wan-Yu Lin; Chia-Hung Kao
Journal:  Cancer Imaging       Date:  2012-10-26       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.